BMS appoints lung cancer specialist as EVP and CSO

Bristol-Myers Squibb has appointed Dr. Thomas J. Lynch, Jr. executive vice president and chief scientific officer, effective March 16, 2017.

Lynch will succeed Dr. Francis Cuss, who will retire from the company. Dr. Lynch will step down from the Board of Directors of Bristol-Myers Squibb, effective March 15, 2017.

Giovanni Caforio, M.D., chief executive officer and chairman designate of Bristol-Myers Squibb said, “Tom is an internationally recognized oncologist known for his leadership in the treatment of lung cancer and has made significant contributions to the field of targeted therapies throughout his career. Tom brings deep industry knowledge and a sophisticated understanding of the Bristol-Myers Squibb Research & Development program from his experience as a member of our Board. As we transition to our next phase of growth, we are confident Tom is the right person to lead our dynamic R&D organization as we focus on accelerating the development of our Immuno-Oncology medicines and fully realizing the extraordinary potential of our diverse, innovative pipeline. With deep experience as a clinical researcher, leader of large research centers and a practicing physician, Tom brings unique, important and timely perspectives to the business.”